KKR to Present at the Morgan Stanley Financials Conference 2018

NEW YORK--(BUSINESS WIRE)-- KKR & Co. L.P. (NYSE: KKR) announced today that Scott C. Nuttall, Co-President and Co-Chief Operating Officer, will present at the Morgan Stanley Financials Conference 2018 on Wednesday, June 13, 2018 at 1:25 PM ET.

A live audio webcast of the presentation will be available on the Investor Center section of KKR’s website at http://ir.kkr.com/kkr_ir/kkr_events.cfm. For those unable to listen to the live audio webcast, a replay will be available on the website shortly after the event.

Any questions regarding the webcast may be addressed to KKR’s Investor Relations group at [email protected].

ABOUT KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic manager partnerships that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR's investments may include the activities of its sponsored funds. For additional information about KKR & Co. L.P. (NYSE: KKR), please visit KKR's website at www.kkr.com and on Twitter @KKR_Co.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180531006473/en/

Investor Relations:
Kohlberg Kravis Roberts & Co. L.P.
Craig Larson
877-610-4910 (U.S.) / 212-230-9410
[email protected]
or
Media:
Kohlberg Kravis Roberts & Co. L.P.
Kristi Huller or Cara Major
212-750-8300
[email protected]

Source: KKR & Co. L.P.

You May Also Be Interested In

• DentalXChange appoints Scott Hampel as president
• KKR to Acquire IEP Technologies and Newson Gale, Representing the Majority of HOERBIGER’s Safety Business Unit
• IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial